Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-Cirrhosis study of pegozafermin in compensated cirrhosis due to MASH
NL-OMON59613Phase 3Recruiting
- Sponsor
- 89bio
- Start
- Feb 2025
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH), Cirrhosis, sponsored by 89bio. Started Feb 2025; status: recruiting.
02
Drugs
pegozafermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on NL-OMON59613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59613.